Octreotide
Administration
- Type: Octapeptide
- Dosage Forms:
- Routes of Administration: IV, IM, or SQ
- Common Trade Names: Sandostatin, Sandostatin LAR
Adult Dosing
Variceal Bleeding
- Initial Bolus: 50mcg IV (range 25-100mcg)[1]
- Drip rate: 25-50 mcg/hr IV
Sulfonylurea Overdose
- 50-75 mpg SQ or IM every 6 hrs as needed
Pediatric Dosing
Sulfonylurea Overdose
- 1-2 mpg/kg SQ or IM
Special Populations
Renal Dosing
No renal dosing adjustments
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
- Hypoglycemia is rare but more common in older adults and type I diabetics
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
A peptide that mimics endogenous somatostatin. Somatostatin is released by the pancreas, pyloric antrum, and duodenum and inhibits Growth Gormone, Gastrin, Vasoactive intestinal peptide (VIP), Gastrin, Serotonin, and decreases Insulin like growth factor-1 (IGF-1), serotonin and it decreases splanchnic blood flow.
Comments
- Although used in the ED mainly for sulfonylurea overdose and vatical bleeding, it is used in outpatient and inpatient medicine for the treatment of acromegaly, carcinoid tumors, and VIPomas
- Octreotide was originally used as a opiod antagonist and is still used off label as a second/third line therapy for diarrhea from opiod withdrawal because of antidiarrheal properties.[2]
See Also
References
- ↑ Garbuzenko DV. Current approaches to the management of patients with liver cirrhosis who have acute esophageal variceal bleeding. Curr Med Res Opin. 2016:1-9.
- ↑ Carreno JE et al. 24-hour opiate detoxification and antagonist induction at home– the ‘asturian method’: A report on 1368 procedures. Addict Biol. 2002;7(2):243-250.